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Abstract
Background: Trigeminal neuralgia (TN) is a rare severe unilateral facial pain condition. Current guidelines in
trigeminal neuralgia management recommend sodium channel blockers – carbamazepine or oxcarbazepine – as
the first-line treatment. However, the currently available drugs are often associated with poor tolerability resulting in
sub-optimal pain control. CNV1014802 is a novel sodium channel blocker that is being assessed in the treatment of
trigeminal neuralgia. Due to the severity of the condition, it is not ethical to conduct a traditional placebo-controlled
randomized controlled trial. It is also difficult to use an active control such as carbamazepine, the current gold standard,
because of its complex pharmacology and potential for drug interactions.
Methods/Design: The trial uses a randomized withdrawal design to assess efficacy in this rare condition. There is a
21-day open-label phase followed by a randomized 28-day placebo-controlled phase for responders. Thirty patients will
be randomized. The primary outcome measure will be pain relief, but secondary measures of quality of life will be of
significant importance given the effect of this condition on activities of daily living. Safety and adverse event endpoints
are described.
Discussion: There have been very few well-controlled, randomized, placebo-controlled studies in trigeminal neuralgia,
and the majority of drugs have had other primary uses. Due to the severity of the pain, minimizing the time a patient is
administered placebo was a key factor in designing this study. This study will not only provide data on the efficacy of
CNV1014802 in trigeminal neuralgia, but will also provide information on the effectiveness and acceptability of a novel
trial design in trigeminal neuralgia.
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Background
Trigeminal neuralgia (TN) is an uncommon episodic
severe facial pain condition with an incidence of 4.0 to 4.7
per 100,000 persons per year [1,2]. Trigeminal neuralgia
can appear at any age, but disease onset is over 40 years
of age in over 90% of cases with peak onset between 50
and 70 years of age [2,3]. However, recent data from
primary care practice data validated by experts suggest
an incidence rate of 12.6 per 100,000 person years with
a mean age at diagnosis of 51.5 (SD 17.6) with a female
predominance 71% [4]. The classification system of the
International Headache Association aims at establishing
TN diagnostic criteria based on etiology [5]. Yet, there
is a problem in distinguishing primary and secondary
TN, because unless a patient with normal neuroimaging
comes to an operation, it remains unclear if his/her TN
is caused by a vascular compression. To adjust for this
diagnostic uncertainty, the term “classical” neuralgia is
currently used for cases with normal neuroimaging
and potential compression of the proximal trigeminal
nerve root by a vascular loop. Classical TN is the most
common TN type, and it is thought that secondary
demyelination, probably mediated by microvascular ische-
mic damage, results in a lowered excitability threshold
of affected neurons. This promotes inappropriate ectopic
generation of spontaneous nerve impulses together with
abnormal nonsynaptic ephatic transmission to adjacent
neurons [6,7].
Unlike many other neuropathic pains, TN results in
recurrent paroxysms of short-lasting but very severe pain
in the distribution of one or more branches of the
trigeminal nerve. In patients with the classical type,
the attacks come on suddenly, last up to 2 min and
disappear suddenly. Between attacks, patients are usually
asymptomatic, although there may be a slight after pain
[8]. Numerous attacks occur a day, but currently there
are no studies detailing how many paroxysms occur a
day. In a recent RCT of botulinum toxin A in 42 TN
patients, the frequency of paroxysms was measured,
and the average was 20 a day, but the range was 4–100
[9]. Patients also report that these can be so frequent
that it seems like one long attack. The attacks can vary
in severity and be described as shooting, electric shocks
scoring maximum scores on scales or just “twinges.” These
attacks can then go on for weeks or months. Especially
in the early stages of the disorder, it is very common
for the attacks to stop completely and for patients to
have weeks, months or even years of no pain [10].
However, over time the remission periods get shorter.
Currently, there are no natural history studies or known
prognostic factors to help determine how long these
periods can be, although Taylor et al. [11] showed that
carbamazepine became less effective with time. This
may be due to the natural course of the disease, but may
also be vested in the autoinduction pharmacological
properties of carbamazepine itself. Pain is provoked by
light touch activities, e.g., washing, eating, talking and
cold winds, but spontaneous attacks of pain also occur.
One study that measured the occurrence of evoked or
spontaneous pain suggested that oxcarbazepine was
more effective at reducing the former [12]. Although
attacks of pain occur at night, these are less common.
Thus, even when pain free, patients live in fear of pain
return. These features therefore make it difficult to
evaluate the effect of treatments. The diagnostic criteria
for TN most frequently used are those of the International
Headache Society, the International Classification of
Headache Disorders (ICHD) [13], and these have now
been updated with clearer specification of the variants
of TN, i.e., those patients who may have in addition to
the shooting stabbing pain a more prolonged pain, and
these are thought to have a potentially different patho-
physiology [14].
Current guidelines in trigeminal neuralgia management
recommend sodium channel blockers such as carbamaze-
pine or oxcarbazepine as the first-line treatment for pain
control. However, these agents are often poorly tolerated
[15] and often require lengthy dose escalation, resulting
in sub-optimal efficacy, and some result in significant
drug interactions and require careful monitoring. Other
potential second-line therapies include lamotrigine, prega-
balin, gabapentin and baclofen; there is limited evidence
to support the use of these agents [15,16]. Unlike other
medications used in chronic pain, these drugs often result
in complete pain relief, not just 50%, especially in the
earlier stages of the disorder.
All the drugs used to date have been initially developed
for other uses, principally epilepsy, so dosage scales
have had to be adapted. A review of RCTs and Cochrane
systematic reviews (SR) shows that the major side effects
reported from antiepileptic drugs (AED) were drowsiness
from 100–4%, dizziness or vertigo 47–3%, gastrointestinal
(GI) 57 to- 8%, mood changes 2%, dry mouth or taste
change 4–2%, and headaches 4%. The SR on carba-
mazepine (CBZ) [17] reported 40–60% would have side
effects. However, no study provides details on how these
events were measured or quantified. Studies in healthy
volunteers do show that AED drugs, especially the older
ones such as CBZ, do result in cognitive impairment,
although this is generally modest but can have clinical
significance [18]. Memory, especially those tasks with
an attentional component, is reduced when on CBZ
[19,20]. However, it also needs to be noted that pain
has an impact on cognitive function [21].
Thus, a well-tolerated sodium channel blocker that can
be administered at an effective dose with no titration
and good tolerability may address some of the unmet
needs of this patient group.
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CNV1014802 is a peripherally and centrally acting
agent that inhibits sodium channels in a state-dependent
fashion. CNV1014802 shows selectivity for the Nav1.7
subtype over the other subtypes tested (Nav1.1, Nav1.2,
Nav1.3, Nav1.5, Nav1.6 and TTX-R), for both the resting
and depolarized states. The greater block of Nav1.7 is
particularly enhanced at concentrations below 1 μM,
where the free exposure in animal models and human
clinical doses lies.
In addition, the amount of block by CNV1014802
increases significantly and in a similar way with the
frequency of stimulation for Nav1.7, Nav1.2 and
Nav1.6. Combining all aspects of the pharmacology
of CNV101802 at sodium channels, the block is more
activity-driven at Nav1.2 and Nav1.6 than it is at
Nav1.7, where it is substantial even at lower levels of
activity of the channel. The block at Nav1.5 and
TTX-R is significantly weaker.
Consistent with its mechanism of action, CNV1014802
will preferentially target and inhibit higher frequencies of
firing (from 10 Hz onwards) that are attained following
noxious stimuli or occur in chronic pain conditions or
during seizure activity.
CNV1014802 has also been shown to selectively and
reversibly inhibit the monoamine oxidase (MAO)-B en-
zyme, with no effect on MAO-A. One hundred percent
inhibition of MAO-B was achieved with doses of 75 mg
and above in the clinic studies.
A genetic substrate for neuropathic pain is an accepted
hypothesis in the scientific community. Recently, sodium
channel gene mutations causing cell hyperexcitability
have been identified in groups of patients with painful
neuropathy [22,23]. Calcium channelopathies have also
been linked to migraine and epilepsy [24]. Given the
importance of sodium and calcium channels in the
generation, propagation and plasticity of pain signals,
it is proposed to genotype five sodium channel (Nav1.1,
Nav1.2, Nav1.3, Nav1.6 and Nav1.7) and two calcium
channel (Cav2.2 and Cav2.1) genes in all patients entering
the study to explore whether mutations in these genes
are present in TN and whether these are related to
response to treatment with CNV1014802.
CNV1014802 has completed extensive phase I studies
with single and repeated doses in 166 healthy volunteers.
Moore et al. [25] in their analysis of analgesic drugs
propose that high failure rates of drugs must be expected
especially in chronic pain, that a radical re-think is
necessary in the design of analgesic trials and that an
enhancement enriched randomized withdrawal design
may be the way forward, but currently they are poorly
understood in part because few have been carried out.
Thus, the aim of this study is to design and test a
protocol to evaluate the efficacy of a new sodium channel
blocker, CNV1014802, in TN, which takes into account
the difficulties encountered in previous trials in this
area. An additional aim, if study participants agree, is
genotyping for possible sodium and calcium chan-
nelopathies. The protocol was designed and approved
prior to the SPIRIT 2013 statement, but will try to
adhere to the published check list [26].
Methods and design
A review of the literature was first carried out and showed
that clinical trials in TN are challenging, and many of
the published trials in this disorder have recruited low
numbers of patients and have used variable designs and
outcome measures, resulting in inconclusive outcomes
[17,27-29]. Traditional placebo-controlled studies (cross-
over or parallel group) are difficult to run in this condi-
tion, as significant numbers of patients will be exposed
to placebo for an extended duration. Using active controls
is difficult as the gold standard drug carbamazepine is
metabolized through the liver and so takes time to be
eliminated and for the liver enzymes to return to normal
function, thus necessitating extended washout periods.
Because of the severe nature of the pain, patients are
unlikely to accept extended periods of no treatment or
use of placebos. Two-stage enhancement enriched
randomized withdrawal designs (EERW) have recently
been proposed as an alternative strategy for determining
the effectiveness of analgesic drugs [30,31]. Although
bias will occur as only responders are enrolled into the
randomized part of the trial and they may also guess
whether they are on the active drug or not, it does offer
the patients a rapid termination and return to previous
medication. Response to the open label part of the study
also allows any adjustments to be made to the dosage
and to evaluate whether the drug has any potential in
the individual patient. A recent study using levetiracetam
for TN showed poor efficacy in the open label phase, so
the randomized trial was not started [32]. With a disorder
that results in unexpected remission periods, it is essential
to ensure that at the end of the trial it is established
that the disease has not gone into remission.
Outcome measures were chosen according to the
recently published recommendations from the Inter-
national Association for the Study of Pain committee
[33], which suggest the following areas should be assessed
using psychometrically tested tools: pain intensity, physical
and emotional functioning, participants global improve-
ment and satisfaction, symptoms and adverse events,
and participants disposition. Trigeminal neuralgia is
unusual in that it is considered a chronic pain, but the
pain is very clearly episodic. Attacks can vary in number
and anecdotally patients have reported that a significant
outcome is to have a reduction in pain attacks even if their
intensity remains high. In an RCT of use of lamotrigine
in TN, a composite score was obtained that included
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the number of bursts of pain, i.e., not individual stabs
of pain but paroxysms of pain (none, 1–3, 4–7, 8–12,
13–20, over 20), severity of pain (no pain, mild, moderate,
severe) and degree of pain relief (complete, good, moder-
ate, slight, none) [34]. Thus, the number of paroxysms
daily would also be used as an outcome measure, although
there are no data on the number of attacks expected,
but a 50% reduction would be considered successful.
The pain intensity of each paroxysm is assessed on an
11-point numerical rating scale (PI-NRS). The Brief
Pain Inventory-Facial (BPI-Facial), which is a validated
18-item rating scale for facial pain in a TN population
[35], is also included as a composite assessment of efficacy,
which includes the impact of pain on quality of life.
Special emphasis will be placed on adverse events as
drugs such as carbamazepine are highly effective, but
their tolerability is very poor, thus limiting their use. A
scale that has been developed and tested in large numbers
of patients with epilepsy is the adverse events profile
(AEP) by Baker et al. [36,37]. This would provide more
quantifiable data than have previously been reported.
Although measuring cognitive function is complex
and it has been suggested that self-administered scales
may have a much stronger relationship to participants’
mood rather than their objectively measured cognitive
performance, some attempt will be made to measure
this using the Medical Outcomes Study-Cognitive Scale
(MOS-Cog) [38,39].
Genotyping is not mandatory for patients participating
in the study.
The trial was designed by the chief investigator (JZ)
and the Convergence team with protocol review by two
outside neurologists with experience in this disorder
and later by two of the authors (MO; DE) Additional
file 1. A brief summary of the trial was presented at a
UK Trigeminal Neuralgia support group meeting to
determine whether patients would take part in the
study and whether the correct outcome measures were
chosen. Expert patients were asked to comment on the
patient information sheet, consent form and diary card.
The study has been approved by regulatory authorities
and ethics committees in 11 countries: the UK, Germany,
Switzerland, Estonia, France, Italy, Latvia, Lithuania,
Romania, South Africa and Spain. The names of the
committees are to be found in the Additional file 2,
Ethics Committees. Although it is anticipated that patients
will be referred in from the community, the study will
take place in secondary care centers, which have a special
interest in headache and facial pain.
The trial was designed to use an initial dose of 150 mg
three times daily with the flexibility to use a higher dose
regimen of 350 mg twice daily if appropriate. A review
of efficacy data after the first ten patients had completed
the open label study was planned to review efficacy and
tolerability. If these were acceptable, as judged by a data
monitoring committee, then the trial would continue to
completion without changing the dose. All investigators
and their teams met for 1 day to undertake training and
review the protocol, and the operational practicalities
of the study including site selection, monitoring and
data management were taken over by a contract research
organization (CRO).
The outline protocol is available at www.clintrials.gov,
trial no. NCT01540630, and gained ethical approval in
the UK in September 2011, then subsequently in all the
other participating countries. A final harmonized version
of the protocol, incorporating all country-specific minor
amendments, was available in August 2013.
A double-blind, randomized withdrawal study compar-
ing CNV1014802 with placebo in patients with TN who
have successfully responded to CNV1014802 in an initial
open-label phase was designed to take into account
all the difficulties highlighted in the Methods section.
Figure 1 shows the overall design of the study.
Design
Patients participate in an initial open-label treatment
period of 21 days of CNV1014802 using 150 mg three
times daily. Responders are then randomized to 28 days
of CNV1014802 150 mg three times daily or placebo.
A responder at the end of the open-label period was
defined as a patient with one of the following:
 A 30% or more decrease in the total number of
paroxysms over the last 7 days of the open-label
phase as compared to the total number recorded in
the 7-day baseline phase (day −7 to −1 prior to start
of study medication)
 A 30% reduction in the mean severity of pain
experienced during the paroxysm over the last 7
days of the open-label phase as compared to the
total number recorded in the 7-day baseline phase
(day −7 to −1 prior to start of study medication)
 A Patient Global Improvement of Change rating of
much improved/very much improved
Randomization and allocation concealment mechanism
In the initial open-label treatment period, all patients
will receive CNV1014802.
Patients will be randomized to CNV1014802 or placebo,
in a 1:1 ratio, in accordance with the randomization
schedule. The randomization schedule will be generated
by the CRO using the PROC PLAN procedure of SAS®,
a validated computer system. Eligible patients will be
randomized into the study on day 21. The randomization
schedule will be stratified by whether the patient is on
existing pain medication (adjunct) or not (monotherapy).
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Equal numbers of patient on adjunct and monotherapy
are not required.
Outcome measures
The primary outcome measure of efficacy is the number
of treatment failures on CNV1014802 vs. number of treat-
ment failures on placebo throughout the double-blind
treatment period. Patients are classified as a treatment
failure if they meet one of the following criteria:
i. A 50% increase in the frequency of paroxysms
compared to the final 7 days of the open-label period
to more than three paroxysms within a 7-day period
ii. When more than three paroxysms are reported in a
7-day period, a 50% increase in the severity of pain
experienced in the paroxysms compared to the final
7 days of the open-label period
iii. A Patient Global Improvement of Change rating of
much worse/very much worse
iv. The patient discontinues the study because of ‘lack
of efficacy.’
v. The patient discontinues because of an adverse
reaction or poor tolerability considered to be related
to the study medication
During the double-blind randomized phase, patients
will be evaluated to determine whether they meet the
failure criteria at each clinic visit, which will occur every
7 days in the double-blind treatment period. The data
for the frequency and severity of the pain will be taken
from the daily diaries completed by the patients. Figure 2
is an example of such a diary.
Secondary outcome measures of efficacy are:
 Proportion of failures by week
 Kaplan-Meier analysis of time to failure
 Average change in the pain intensity numerical
rating scale PI-NRS by week
 Average change in PI-NRS (best response)
 Median change in the number of paroxysms by week
 Median change in the number of paroxysms
(best response)
 Patient and physician global impression of change
 Average change in the Brief Pain Inventory
BPI-Facial by week [35]
 Average change in the BPI-Facial (best response)
 Number and severity of paroxysms of pain in the
21-day open-label period, both evoked and
spontaneous
 Average 24-h pain intensity numerical rating scale
(PI-NRS)
 Patient and Physician Clinical Global Impression
of Change
Other measures will include:
 Adverse events, vital signs, ECG and safety laboratory
samples will be collected throughout the study
 Adverse event profile: this questionnaire was
developed for epilepsy to understand the common
AEs associated with epilepsy [36,40], collecting it at
screening, day 21 and the last day in the study to try
and compare tolerability on CNV1014802 compared
to other anti-epileptics they may be taking at screening.
 Medical Outcomes Study-Cognitive Scale (MOS-Cog)
will be completed at screening and the end of the
study [38,39]
 Assessment of blindedness of study medication:
Both the patient and clinician will provide a guess
as to which medication (CNV1014802 or placebo)
was administered during the double-blind
treatment period
 Pre- and post-dose plasma concentrations of
CNV1014802
 Presence of genetic mutations in sodium channel
(Nav1.1, Nav1.2, Nav1.3, Nav1.6 and Nav1.7) or
calcium channel (Cav2.2 and Cav2.1) genes
If the patient requires a drug treatment for their TN
pain other than paracetamol, they will be considered a
Figure 1 Design of the study.
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treatment failure, also if they develop any of the following:
seizure or suspected seizure, elevated hepatic transami-
nases, QT prolongation, drug-related rash, and moderate
to severe CNS adverse events.
Inclusion and exclusion criteria
All patients are aged 18 to 80 years of any gender. The
main inclusion and exclusion criteria are shown in Table 1;
the others are listed on the website www.clintrials.gov, trial
no. NCT01540630.
Patients must have classical trigeminal neuralgia ful-
filling all the criteria of the IHS [13]. They must have
suffered a minimum of three or more paroxysms of
pain per day, rated at an intensity of 4 or more on the
pain NRS, on at least 4 days during the last 7 days prior to
entry into the open-label treatment period. The following
patient categories may be considered for the study:
suboptimal responders or intolerant to sodium channel
blockers, responders to sodium channel blockers who
are willing to be washed out from any sodium channel
blockers prior to the run-in period, suboptimal responders
to pregabalin or gabapentin, recurrence of trigeminal
neuralgia following a remission including (but not limited
to) patients who have previously had a positive response
to surgery, treatment naïve and on waiting list for surgery.
It is considered useful for all patients to have had
some form of imaging done to exclude symptomatic TN
and also to have had a dental examination to exclude
any potential dental causes. Patients with significant
autonomic symptoms or other neuropathic pain are to
be excluded.
In view of the fact that CNV1014802 is extensively
metabolized, and that the drug interaction potential in
humans has not yet been fully evaluated, a variety of drug
types have to be stopped prior to study commencement,
and approved concomitant medications must have been
stable for at least 3 weeks prior to day 0. This includes but
is not limited to sodium channel blockers or drugs that
adversely interact with a monoamine oxidase-B inhibitor:
MAOIs, antidepressants, opioids and sympathomimetic
agents. Other than gabapentin and pregablin, no other
antiepileptic drug (AED) is allowed.
Among the exclusion criteria are patients who are
known non-responders to sodium channel blockers at
therapeutic doses and those with a history of uncontrolled
or poorly controlled hypertension. Patients with a history
or presence of significant cardiovascular, gastrointestinal
or renal disease or other condition known to interfere with
the absorption, distribution, metabolism or excretion of
drugs are also excluded.
The rescue medication is paracetamol only to a max-
imum dose of 4 g/day.
As the trial is intended to be carried out in multiple
countries, it is crucial to ensure that only classical TN
patients are recruited and not those whose diagnosis is
equivocal and who had tried a large number of drugs
with poor response. The data-monitoring committee
(DMC) is made up of three clinical investigators with
experience in diagnosing patients with TN (JZ, DE, MO),
the medical director and study manager from Conver-
gence and from the CRO medical monitor, statistician
and project leader. Their remit as well as verifying the
diagnosis is to evaluate ongoing efficacy and safety data
from the open-label period and to recommend: the
dose of CNV1014802 to be used following review of
the first ten evaluable subjects completing the open-label
Figure 2 Pain diary completed by the patient on a daily basis.
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period. All patients considered for screening are required
to complete a two-page form on diagnostic criteria to be
considered by the DMC and approved by at least two of
the investigators. The DMC also receives weekly reports
on the progress of the trial and numbers required from
each center and their progress through the study. It can
also terminate the study depending on the efficacy and
tolerability of the drug.
All the data from the trial are collected on electronic
clinical record forms and anonymized prior to submission,
Table 1 CNV1014802 in patients with trigeminal neuralgia inclusion and exclusion criteria
Major inclusion criteria Major exclusion criteria
A patient will be eligible for inclusion in this study only if all
of the following criteria apply:
A patient will not be eligible for inclusion in this study if any of the
following criteria apply:
1. The following diagnostic criteria for trigeminal neuralgia
must be met:
1. Patients who are known non-responders to sodium channel blockers
at therapeutic doses. If patients have previously been unable to tolerate
sodium channel blockers and therefore has not been able to take doses
within the therapeutic dose range, they may still be included.Paroxysmal attacks of pain lasting from a fraction of a second to
2 min affecting one or more divisions of the trigeminal nerve
Pain has at least one of the following characteristics:
i. Intense, sharp, superficial or stabbing
ii. Precipitated from trigger areas or by trigger factors
iii. Attacks are stereotyped in the individual patient
There is no clinically evident neurological deficit
Not attributed to another disorder
2. Frequency criteria for numbers of paroxysms: 2. A positive history of HIV.
Patients must have suffered a minimum of 3 or more paroxysms of
pain per day, rated at an intensity of 4 or more on the pain NRS,
on at least 4 days during the last 7 days prior to entry into the
open-label treatment period.
3. Male or female between 18 and 80 years of age inclusive at the
time of signing the informed consent.
3. A positive pre-study hepatitis B surface antigen or positive hepatitis C
antibody result within 3 months of screening.
4. A female patient is eligible to participate if she is of non-childbearing
or child-bearing potential and agrees to use one of the contraception
methods listed.
4. History of any liver disease within the last 6 months, with the exception
of known Gilbert’s disease.
5. Male patients must agree to use one of the contraception methods. 5. History of excessive regular alcohol consumption within 6 months of the
study defined as: an average weekly intake of >28 units or average daily
intake >4 units for males; an average weekly intake >21 units or average
daily intake >3 units for females. One unit is equivalent to 8 g of alcohol:
a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure
of spirits.
6. Body weight ≥ 50 kg for men and ≥ 45 kg for women. 6. Patients with a history or risk of seizures or a history of epilepsy, head
injury or related neurological disorders.
7. BMI ≤34.9. 7. Patients with a history of uncontrolled or poorly controlled hypertension.
8. Capable of giving written informed consent, which includes
compliance with the requirements and restrictions listed in the
consent form. Informed consent must be obtained prior to the
commencement of any study-related procedures.
8. History or presence of significant cardiovascular, gastrointestinal, or
renal disease or other condition known to interfere with the absorption,
distribution, metabolism or excretion of drugs, which, in the opinion of
the investigator, may interfere with the study procedures or compromise
patient safety.
9. Patients with conditions known to affect cardiac conduction or a
personal or familial history of Brugada syndrome.
10. Females of child-bearing potential only: pregnant females as determined
by positive urine or serum hCG test at screening or prior to dosing.
11. Lactating females.
12. History or presence of any clinically significant abnormality in vital signs/
ECG/laboratory tests, or any medical or psychiatric condition, which, in the
opinion of the investigator, may interfere with the study procedures or
compromise patient safety.
13. The patient has a history of suicidal ideation and/or suicide attempts.
14. The patient has clinical evidence of recent major depression
(by patient’s medical history).
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and each site is visited by the project lead and local
lead from the CRO. All investigators must adhere to
Good Clinical Practice (GCP) and have undergone the
appropriate training. All the investigational site staff
took part in the protocol training program, either face
to face or web based.
The study is double-blind and there are strict restric-
tions on unblinding. The investigator or treating physician
may unblind a patient’s treatment assignment only in
the case of an emergency, when knowledge of the study
treatment is essential for the appropriate clinical man-
agement or welfare of the patient.
Pharmacovigilance staff acting on behalf of the sponsor
may unblind the treatment assignment for any patient
with a serious adverse event (SAE). If the SAE requires
that an expedited regulatory report be sent to one or more
regulatory agencies, a copy of the report, identifying the
patient’s treatment assignment, may be sent to clinical
investigators in accordance with local regulations.
Power calculation
The aim is to enroll sufficient patients to randomize 30
responders into the double-blind randomized phase of
the study. If evaluable data are available from 22 patients
entering the randomized phase, assuming a 20% failure
rate for CNV1014802 and a 67% failure rate for placebo,
11 evaluable patients per treatment arm (22 in total)
would provide 80% power to detect a difference of 47%
between the proportion of failures on CNV1014802 and
placebo, assuming a one-sided test with a type I error
rate of 5%.
Discussion
This is the first time that such a design has been used
to evaluate a drug for TN. It is also the first time that
a drug is being used that has not first been evaluated
in epilepsy. Its design conforms with the CONSORT
guidelines, which have been shown to improve the
quality of trial reporting [41], and although conceived
before the statement on defining the standard protocol
for clinical trials was published, it does conform to
these [26]. Drug trials in TN are rare, heterogeneous
and often contain serious methodological issues. Only
11 randomized placebo controlled trials on classical TN
have been conducted since 1967. These trials recruited
very different patient numbers (ranging from 3 to 77
participants), often embedding TN patients into a broader
facial pain patient spectrum study to gain more statistical
power. Formal power calculations were generally not
provided in most previous TN trials. The study by Gilron
et al. [42] is an extreme example of recruitment difficulties
that all TN trials face. This placebo-controlled, multiple
cross-over pilot study included only three patients. The
present study is also small and needs to be regarded as
a pilot, which will enable more accurate power calculations
to be performed in the future. The primary outcome
measure chosen is pain relief as is the norm for pain trials,
yet it may be that other outcomes such as improved
quality of life due to reduced side effects may be of
greater importance. Many patients report that the “odd
twinge” does not significantly impact on their lives, but
tiredness, impaired cognitive function and ataxia from
the high-dose medication has a significant impact on
activities of daily living.
Most centers specialized in the treatment of patients
with TN do not have a large enough patient base of the
right type of patients including those willing to have
their medication regimens changed.
A variety of strategies has been suggested to increase
recruitment to trials of both participants and clinicians,
and a recent systematic review suggests increased education
of clinicians about the benefits of RCTs is needed [43].
Thus, the sites chosen have a special interest in TN with
experienced clinicians, and it is hoped they will be able to
recruit the appropriate patients. It takes time to recruit
patients to clinical trials, and there are few data available on
this topic. A recent study of an orthodontics multicenter
RCT showed that it took on average 19 min to recruit a
patient to the study and then a further 110 min per patient
to fully recruit to the study and ensure all administrative
data were available [44]. The variations between the
centers were large in respect to the administrative data
time as it often depended on the research support staff
that was available. There was also considerable time
involved in meetings of the principal investigators, and
the authors suggest that these timings are potentially
much higher in more complex studies.
To improve recruitment to this trial ethics approved data
for patients were prepared and distributed to clinicians
attending relevant conferences and for placement in a
Trigeminal Neuralgia Support group newsletter in the
UK. Recruitment of patients could be problematical for
other reasons that are specific to this condition. TN
causes very severe pain, and once stabilized on medications
patients are often reluctant to change for fear their pain
will return or become unmanageable. They may have
used a range of other AEDs including the two permitted
ones in the past and so be reluctant to go back to
them. Currently the most effective AEDs cannot be
used. Patients with classical TN who have neurovascular
compression of the nerve (seen on MRI) may opt to
have an operation rather than try further medications
as the outcomes from surgery can be better [15]. The
population most at risk is the elderly, and they are
likely to have medical conditions that preclude their
inclusion in the trial.
Different disease definitions as well as imprecise
allocation of non-standardized diagnostic criteria make
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comparison of the different patient populations virtually
impossible. Many trials do not refer to any particular
diagnostic criteria at all but are content to describe
their patient as having classical TN without further
clarification or definition of that term. This study uses
the international classification of headache disorders
(ICHD-3beta) and an experienced data management
committee to ensure a standardized patient selection
and prevent non-classical TN patients entering the trial.
Incomplete or insufficiently defined outcome parameters,
which were not clearly stated in many of the RCTs
conducted until now, is another serious problem. Many
trials failed to report dropouts or withdrawals, while those
that did report these measures did not use intention-
to-treat analysis to analyze their study results. This is
particularly problematic since the dropout and withdrawal
rates in most TN trials are very high. Information on
demographics and clinical characteristics of the different
treatment groups is often incomplete and lacks a clear
comparison of baseline data with regard to gender, age,
duration of disease and pain scores.
Allocation concealment and blinding are often prob-
lematic in randomized controlled trials on TN. Often
blinding methods are not reported in detail, so that it
remains unknown who was blinded to what. All of
these trials stated that they were randomized, but most
did not describe the utilized method of randomization
or whether the randomization method used was effective
in regard to homogenizing the groups that were to be
compared in the final analysis.
Selective reporting is generally considered a minor
problem in these small and often confined studies. Some
studies however did not clearly state what assessment
tools they used for their analysis, while others did not
report the adverse events or side effects of the study
drug consistently. The possibility of patients going into
spontaneous remission with treatment or without was
not raised by most authors when interpreting their data.
Other potential sources of bias were often underre-
ported. Many studies use the investigated drug as add-on
to carbamazepine or other established treatment regimens
[34,43,45-49]. Considering the pharmacologic profile of
carbamazepine and other frequently used antiepileptic
drugs with many drug interactions and hepatic metab-
olism, this may also pose serious consequences to the
trial outcome and data interpretation of these trials
that we are only starting to marginally comprehend.
One of the largest RCTs comparing carbamazepine and
oxcarbazepine in 46 patients has only been reported as
a conference abstract, and the other study, possibly the
same one in a German journal, included 48 patients [50].
The EERW design is new, and there will be few trials
against which to compare the results, but the outcome
measures being used are from the range of those
suggested by Dworkin et al. [33]. The recently extended
Brief Pain Inventory [35] has been psychometrically
tested but has not yet been tested in terms of sensitivity
to change; however, the first section has been used
in extensive analgesic trials and so outcomes can be
compared.
This protocol is being published prior to the study being
completed in accordance with the recent literature [51]
so that it will be possible to compare what was
intended and what was actually done, and it has been
registered on a trials register since February 2012, which
may help to recruit patients. A comparison of registered
and published primary outcome measures in RCTs shows
selective outcome reporting is still prevalent [52], but
this may also be due to an incorrect choice of outcome
measures. In this study it is difficult to determine how
large a change can be expected as there are currently
so few data in the RCTs on TN, and unlike other pain
trials, 100% pain relief can be achieved as opposed to
the usual 50%.
The results of the trial will be published and presented
at conferences including those for patients.
Trial status
Ongoing
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